Back to Search Start Over

Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study.

Authors :
Short SS
Kastenberg ZJ
Wei G
Bondoc A
Dasgupta R
Tiao GM
Watters E
Heaton TE
Lotakis D
La Quaglia MP
Murphy AJ
Davidoff AM
Mansfield SA
Langham MR
Lautz TB
Superina RA
Ott KC
Malek MM
Morgan KM
Kim ES
Zamora A
Lascano D
Roach J
Murphy JT
Rothstein DH
Vasudevan SA
Whitlock R
Lal DR
Hallis B
Bütter A
Baertschiger RM
Lapidus-Krol E
Putra J
Tracy ER
Aldrink JH
Apfeld J
Le HD
Park KY
Rich BS
Glick RD
Fialkowski EA
Utria AF
Meyers RL
Riehle KJ
Source :
Cancer [Cancer] 2022 Jul 15; Vol. 128 (14), pp. 2786-2795. Date of Electronic Publication: 2022 May 13.
Publication Year :
2022

Abstract

Background: Hepatocellular carcinoma (HCC) is a rare cancer in children, with various histologic subtypes and a paucity of data to guide clinical management and predict prognosis.<br />Methods: A multi-institutional review of children with hepatocellular neoplasms was performed, including demographic, staging, treatment, and outcomes data. Patients were categorized as having conventional HCC (cHCC) with or without underlying liver disease, fibrolamellar carcinoma (FLC), and hepatoblastoma with HCC features (HB-HCC). Univariate and multivariate analyses identified predictors of mortality and relapse.<br />Results: In total, 262 children were identified; and an institutional histologic review revealed 110 cHCCs (42%; 69 normal background liver, 34 inflammatory/cirrhotic, 7 unknown), 119 FLCs (45%), and 33 HB-HCCs (12%). The authors observed notable differences in presentation and behavior among tumor subtypes, including increased lymph node involvement in FLC and higher stage in cHCC. Factors associated with mortality included cHCC (hazard ratio [HR], 1.63; P = .038), elevated α-fetoprotein (HR, 3.1; P = .014), multifocality (HR, 2.4; P < .001), and PRETEXT (pretreatment extent of disease) stage IV (HR, 5.76; P < .001). Multivariate analysis identified increased mortality in cHCC versus FLC (HR, 2.2; P = .004) and in unresectable tumors (HR, 3.4; P < .001). Disease-free status at any point predicted survival.<br />Conclusions: This multi-institutional, detailed data set allowed a comprehensive analysis of outcomes for children with these rare hepatocellular neoplasms. The current data demonstrated that pediatric HCC subtypes are not equivalent entities because FLC and cHCC have distinct anatomic patterns and outcomes in concert with their known molecular differences. This data set will be further used to elucidate the impact of histology on specific treatment responses, with the goal of designing risk-stratified algorithms for children with HCC.<br />Lay Summary: This is the largest reported granular data set on children with hepatocellular carcinoma. The study evaluates different subtypes of hepatocellular carcinoma and identifies key differences between subtypes. This information is pivotal in improving understanding of these rare cancers and may be used to improve clinical management and subsequent outcome in children with these rare malignancies.<br /> (© 2022 American Cancer Society.)

Details

Language :
English
ISSN :
1097-0142
Volume :
128
Issue :
14
Database :
MEDLINE
Journal :
Cancer
Publication Type :
Academic Journal
Accession number :
35561331
Full Text :
https://doi.org/10.1002/cncr.34256